Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy. (1st February 2017)

• Record Type: Journal Article
• Authors: Lazear, Eric; Ghasemi, Reza; Hein, Sarah M.; Westwick, John; Watkins, Dan; Fremont, Daved H.; Krupnick, Alexander Sasha
• Is Part Of: Oncoimmunology. Volume 6:Number 2(2017)
• Publication Date: 2017-02-01
• Subjects: Cytokine -- cytotoxic lymphocytes -- immunotargeting -- immunotherapy -- Interleukin-2 (IL-2) -- natural killer cell (NK) -- NKG2D; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2016.1265721
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic lymphocytes using a virally encoded immune evasion protein and an IL-2 mutant that avoids off-target side effects such as activation of regulatory T cells and vascular endothelium.